GUADECITABINE for Transitional cell carcinoma metastatic: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 6 adverse event reports in the FDA FAERS database where GUADECITABINE was used for Transitional cell carcinoma metastatic.
Most Reported Side Effects for GUADECITABINE
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Febrile neutropenia | 21 | 25.9% | 3 | 17 |
| Neutropenia | 16 | 19.8% | 2 | 9 |
| Anaemia | 12 | 14.8% | 5 | 9 |
| Thrombocytopenia | 12 | 14.8% | 1 | 5 |
| Constipation | 11 | 13.6% | 1 | 8 |
| Neutrophil count decreased | 9 | 11.1% | 6 | 6 |
| Abdominal pain | 8 | 9.9% | 2 | 8 |
| Fatigue | 8 | 9.9% | 4 | 4 |
| Platelet count decreased | 8 | 9.9% | 5 | 6 |
| Sepsis | 8 | 9.9% | 8 | 5 |
| Back pain | 7 | 8.6% | 1 | 7 |
| Nausea | 7 | 8.6% | 2 | 2 |
| Pneumonia | 7 | 8.6% | 4 | 7 |
| Urinary tract infection | 7 | 8.6% | 0 | 7 |
| Vomiting | 7 | 8.6% | 5 | 5 |
Other Indications for GUADECITABINE
Myelodysplastic syndrome (21)
Product used for unknown indication (9)
Ovarian cancer recurrent (7)
Acute myeloid leukaemia (5)
Chronic myelomonocytic leukaemia (5)
Leukaemia (5)
Other Drugs Used for Transitional cell carcinoma metastatic
ENFORTUMAB VEDOTIN-EJFV (390)
PEMBROLIZUMAB (245)
AVELUMAB (144)
GEMCITABINE (128)
ATEZOLIZUMAB (125)
ENFORTUMAB VEDOTIN (123)
CARBOPLATIN (76)
CISPLATIN (64)
NIVOLUMAB (51)
PACLITAXEL (25)